文献速递乳腺癌放疗

cT1-2N1乳腺癌新辅助化疗后ypN1省略区域淋巴结照射的可行性(KROG 21-06)

Feasibility of omitting regional nodal irradiation in cT1-2N1 breast cancer with ypN1 disease after neoadjuvant chemotherapy (KROG 21-06).
PubMed 文献 · Clin Transl Radiat Oncol · 2026-05-30

该回顾性研究纳入2005–2017年245例临床T1-2N1乳腺癌新辅助化疗后腋窝清扫证实1–3枚阳性淋巴结(ypN1)的患者,84.5%接受了区域淋巴结照射(RNI)。中位随访88.9个月,多因素分析显示RNI与任何生存结局均无关,RNI组与非RNI组5年LRRFS、DMFS、DFS、OS差异均无统计学意义(均p>0.05)。

要点

  • ypN1乳腺癌新辅助化疗后,RNI与LRRFS、DMFS、DFS、OS均无关。
  • RNI组5年LRRFS 89.5% vs 非RNI组97.2%,差异无统计学意义。
  • RNI组5年OS 91.1% vs 非RNI组100%,差异无统计学意义。

核心结论

  • 在cT1-2N1乳腺癌新辅助化疗后ypN1患者中,RNI未带来额外生存获益,该发现尚需进一步验证。

研究设计与样本

  • 回顾性研究纳入2005–2017年接受新辅助化疗、手术及术后放疗的cT1-2N1乳腺癌患者,限定腋窝清扫后1–3枚病理阳性淋巴结(ypN1),共245例。

主要发现

  • RNI组淋巴管侵犯(p=0.009)和结外延伸(p<0.001)更常见,其余患者及肿瘤特征两组相似。
  • 多因素分析中组织学分级与LRRFS显著相关(p=0.045),淋巴管侵犯与DMFS显著相关(p=0.029)。
  • RNI与LRRFS、DMFS、DFS、OS均无显著关联。
  • RNI组与非RNI组5年LRRFS为89.5% vs 97.2%,DMFS为84.2% vs 91.6%,DFS为81.7% vs 91.6%,OS为91.1% vs 100%(均p>0.05)。

关键数值与推荐

  • 入组条件:临床T1-2N1乳腺癌,接受新辅助化疗后手术,腋窝清扫后病理证实1–3枚阳性淋巴结(ypN1)。
  • RNI组与非RNI组5年LRRFS、DMFS、DFS、OS差异均无统计学意义(均p>0.05)。

临床怎么用

  • 对于cT1-2N1新辅助化疗后ypN1乳腺癌患者,省略RNI可能是可行选择,但需结合淋巴管侵犯、结外延伸等个体化评估并等待进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effect of regional nodal irradiation (RNI) in breast cancer patients with 1-3 residual nodal metastases (ypN1) after neoadjuvant chemotherapy (NAC). METHODS: We retrospectively reviewed the medical records of breast cancer patients with clinical T1-2N1 disease who received NAC followed by surgery and postoperative radiotherapy between 2005 and 2017. Patients with 1-3 pathologically positive lymph nodes (ypN1) after axillary dissection were included. Univariate and multivariate analyses were performed to identify the prognostic factors for locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). RESULTS: The median follow-up duration was 88.9 months (range, 5.0-200.1). A total of 245 patients were included and RNI was administered in 84.5% (n = 207). Lymphatic invasion and extranodal extension were more frequent in patients who received RNI compared with those who did not (p = 0.009 and p < 0.001, respectively), while other patient and tumor characteristics were similar between the two groups. On multivariate analysis, histologic grade was identified as a significant prognostic factor for LRRFS (p = 0.045) and lymphatic invasion was significantly associated with DMFS (p = 0.029). However, RNI was not associated with any of the survival outcomes. The 5-year LRRFS, DMFS, DFS, and OS in the RNI and non-RNI groups were 89.5% vs. 97.2%, 84.2% vs. 91.6%, 81.7% vs. 91.6% and 91.1% vs. 100%, respectively (all p > 0.05). CONCLUSION: RNI was not associated with additional survival benefit in cT1-2N1 breast cancer patients with ypN1 disease after NAC. These findings warrant further validation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Park Y, Kim K, Shin KH, et al. Feasibility of omitting regional nodal irradiation in cT1-2N1 breast cancer with ypN1 disease after neoadjuvant chemotherapy (KROG 21-06). Clin Transl Radiat Oncol. 2026. PMID: 42305852. doi:10.1016/j.ctro.2026.101203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。